S. Seeber
About
S. Seeber is a scholar working on Oncology, Molecular Biology and Hematology.
According to data from OpenAlex, S. Seeber has authored 287 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 95 papers in Molecular Biology and 65 papers in Hematology. Recurrent topics in S. Seeber's work include Cancer Treatment and Pharmacology (43 papers), Cancer therapeutics and mechanisms (31 papers) and Chronic Myeloid Leukemia Treatments (26 papers). S. Seeber is often cited by papers focused on Cancer Treatment and Pharmacology (43 papers), Cancer therapeutics and mechanisms (31 papers) and Chronic Myeloid Leukemia Treatments (26 papers). S. Seeber collaborates with scholars based in Germany, United States and Belgium. S. Seeber's co-authors include A. Harstrick, Dirk Strumberg, Martin Stuschke, M. E. Scheulen, H. Wilke, U. Vanhoefer, J. Schütte, M. Stahl, Bertram Opalka and Michael Flaßhove and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
S. Seeber
278 papers receiving 8.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| S. Seeber Germany | 47 | 4.0k | 3.0k | 2.8k | 1.9k | 1.4k | 287 | 9.2k | ||
| Martee L. Hensley United States | 55 | 4.2k 1.0× | 4.7k 1.6× | 1.8k 0.6× | 1.6k 0.8× | 1.5k 1.1× | 223 | 13.3k | ||
| Mark L. Bernstein United States | 48 | 1.8k 0.4× | 2.7k 0.9× | 2.2k 0.8× | 1.1k 0.6× | 785 0.5× | 184 | 7.5k | ||
| Serge Leyvraz Switzerland | 45 | 3.4k 0.8× | 3.2k 1.1× | 1.9k 0.7× | 1.2k 0.6× | 1.3k 0.9× | 214 | 8.5k | ||
| Karen H. Antman United States | 48 | 3.5k 0.9× | 3.3k 1.1× | 1.2k 0.4× | 739 0.4× | 1.2k 0.8× | 146 | 8.4k | ||
| Barth Hoogstraten United States | 30 | 4.9k 1.2× | 3.0k 1.0× | 1.5k 0.5× | 1.6k 0.8× | 910 0.6× | 79 | 9.5k | ||
| Dick J. Richel Netherlands | 43 | 4.5k 1.1× | 1.7k 0.6× | 3.5k 1.3× | 1.6k 0.8× | 769 0.5× | 107 | 9.6k | ||
| S. Monfardini Italy | 52 | 5.0k 1.2× | 2.9k 1.0× | 1.3k 0.5× | 1.5k 0.8× | 637 0.4× | 346 | 10.6k | ||
| Lee S. Rosen United States | 50 | 8.4k 2.1× | 3.8k 1.3× | 3.6k 1.3× | 1.8k 0.9× | 834 0.6× | 232 | 12.1k | ||
| E. Wiltshaw United Kingdom | 43 | 2.8k 0.7× | 1.4k 0.5× | 1.4k 0.5× | 1.5k 0.8× | 1.2k 0.8× | 129 | 7.4k | ||
| Ashley E. Winkler United States | 10 | 3.9k 1.0× | 2.5k 0.8× | 1.1k 0.4× | 1.4k 0.7× | 495 0.3× | 12 | 7.3k |
Countries citing papers authored by S. Seeber
Since
Specialization
Citations
This map shows the geographic impact of S. Seeber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Seeber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Seeber more than expected).
Fields of papers citing papers by S. Seeber
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by S. Seeber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Seeber. The network helps show where S. Seeber may publish in the future.
Co-authorship network of co-authors of S. Seeber
This figure shows the co-authorship network connecting the top 25 collaborators of S. Seeber. A scholar is included among the top collaborators of S. Seeber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Seeber. S. Seeber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dürig, Jan, Peter R. Ebeling, Florian Grabellus, et al.. (2007). A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease. Cancer Research. 67(18). 8653–8661.
2.
Eisele, Lewin, Ludger Klein‐Hitpaß, Bertram Opalka, et al.. (2006). Differential Expression of Drug Resistance-Related Genes between Sensitive and Resistant Blasts in Acute Myeloid Leukemia. Acta Haematologica. 117(1). 8–15.
3.
Bojko, Peter, et al.. (2004). Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Annals of Hematology. 84(2). 110–114.
4.
Nowrousian, Mohammad R., Dieter Brandhorst, Peter R. Ebeling, et al.. (2003). Free light-chain measurement in serum compared with immunofixation of urine in patients with multiple myeloma. Blood. 102(11). 367.
5.
Bojko, Peter, et al.. (2002). Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy. Annals of Hematology. 81(9). 522–528.
6.
Kasimir‐Bauer, Sabine, Dietrich W. Beelen, Michael Flaßhove, et al.. (2002). Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Experimental Hematology. 30(11). 1302–1308.
7.
Kasimir‐Bauer, Sabine, et al.. (2001). Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.. PubMed. 7(6). 1582–9.
8.
Bacher, Gerald, B Nickel, Peter Emig, et al.. (2001). D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.. PubMed. 61(1). 392–9.
9.
Esche, Helmut, et al.. (2000). Transformation-defective adenovirus 5 E1A mutants exhibit antioncogenic properties in human BLM melanoma cells. Cancer Gene Therapy. 7(7). 1043–1050.
10.
Siprashvili, Zurab, Louise Y.Y. Fong, G. Marquitan, et al.. (2000). Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression.. PubMed. 60(11). 2780–5.
11.
Sarbia, Mario, M. Stahl, U. Fink, et al.. (1999). Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. International Journal of Cancer. 84(1). 86–91.
12.
Vanhoefer, U., Wieland Voigt, Ralf A. Hilger, et al.. (1997). Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.. PubMed. 9(9). 485–94.
13.
Vanhoefer, U., Shousong Cao, A. Harstrick, S. Seeber, & Youcef M. Rustum. (1997). Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Annals of Oncology. 8(12). 1221–1228.
14.
Siebert, Reiner, Christoph Willers, Alexander Fosså, et al.. (1996). Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines. Leukemia Research. 20(2). 197–200.
15.
Stahl, M., U. Vanhoefer, U. Fink, et al.. (1996). Phase II Study of Weekly High-Dose 5-Fluorouracil and Folinic Acid plus Biweekly Alternating Cisplatin and Epirubicin (FUFACE) in Patients with Advanced Gastric Carcinoma. Oncology Research and Treatment. 19(5). 416–418.
16.
Harstrick, A., Hans‐Joachim Wilke, Wilfried Eberhardt, et al.. (1996). A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer. Oncology Research and Treatment. 19(2). 153–156.
17.
Thomale, Jürgen, et al.. (1994). Repair of O6-alkylguanines in the nuclear DNA of human lymphocytes and leukaemic cells: analysis at the single-cell level. British Journal of Cancer. 69(4). 698–705.
18.
Wilke, H., P. Preusser, M. Stahl, et al.. (1994). Phase II Study with Folinic Acid, Etoposide, 5-Fluorouracil and Cisplatin (FLEP) for Advanced Gastric Cancer. Oncology Research and Treatment. 17(2). 154–157.
19.
Kloke, O., et al.. (1992). Opposite Sensitivity to the Antiproliferative Action of Interferon-α and Granulocyte-Macrophage Colony-Stimulating Factor in Monoblastic U937 Cells. Journal of Interferon Research. 12(5). 369–376.
20.
Seeber, S., et al.. (1981). Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells. Annals of Hematology. 42(6). 355–365.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Martee L. Hensley Breakdown of academic impact, for papers by Mark L. Bernstein Breakdown of academic impact, for papers by Serge Leyvraz Breakdown of academic impact, for papers by Karen H. Antman Breakdown of academic impact, for papers by Barth Hoogstraten Breakdown of academic impact, for papers by Dick J. Richel Breakdown of academic impact, for papers by S. Monfardini Breakdown of academic impact, for papers by Lee S. Rosen Breakdown of academic impact, for papers by E. Wiltshaw Breakdown of academic impact, for papers by Ashley E. Winkler